RESOLUTION

CDSS2.R1

UPDATE ON MONKEYPOX IN THE REGION OF THE AMERICAS AND ACCESS TO VACCINES

THE SPECIAL SESSION OF THE DIRECTING COUNCIL,

Having reviewed the Update on Monkeypox in the Region of the Americas and Access to Vaccines (Document CDSS2/2);

Recognizing the ongoing valuable efforts by the Pan American Health Organization (PAHO) Revolving Fund for Access to Vaccines (Revolving Fund) to secure access to monkeypox vaccines for the Member States of PAHO;

Reaffirming the principles, terms and conditions, and procedures of the Revolving Fund and its benefit for public health in the Region of the Americas, as ratified by the Member States of PAHO in Resolution CD52.R5 (2013);

Recognizing that the goal of the global response to the monkeypox outbreak is to stop transmission and to effectively use any public health measures to prevent onward spread of the disease, including the use of safe and efficacious vaccines;

Recognizing that the Pan American Sanitary Bureau (PASB) requires the approval of the Member States of PAHO in order to conduct any extraordinary negotiation with manufacturers that may be needed in the current global context,

RESOLVES:

1. To urge Member States to:
   a) promote strategies based on risk communication, surveillance, prevention, and control, focused on transmission mechanisms and contact tracing to limit transmission chains;
b) implement temporary recommendations issued by the WHO Director-General in relation to the multi-country outbreak of monkeypox, as appropriate;

c) continue to recognize PASB and the Revolving Fund as the strategic regional technical cooperation mechanism most suitable for providing equitable access to monkeypox vaccine;

d) promote solidarity and pan-Americanism through participation in the Revolving Fund;

e) promote collaborative studies to fill evidence gaps and scale up pharmacovigilance efforts.

2. To request the Director to:

a) continue to support the Member States of PAHO in implementing a coordinated response to address the multi-country outbreak of monkeypox, specifically in relation to risk communication, surveillance, prevention and control of cases and contacts using pharmacological and non-pharmacological measures, including support for equitable access to monkeypox vaccines, diagnostic kits, and treatments, and promote the strengthening of capacities for the development and production of vaccines and health technologies to deal with health emergencies;

b) continue strengthening the response capacity of the Revolving Fund, promoting its speed, efficacy, and efficiency;

c) provide technical cooperation and strategic support to national authorities to facilitate their access to relevant information needed for decision making, importation, deployment, and oversight of monkeypox vaccines at country level;

d) maintain dialogue with partners and global producers of monkeypox vaccine in an effort to obtain doses of the vaccine for the Region of the Americas;

e) conduct extraordinary negotiations with manufacturers for the best possible price for procurement of monkeypox vaccine for the Region of the Americas, and if necessary, as an exceptional measure, adjust the terms and conditions of the Revolving Fund in order to address the special circumstances that currently exist in order to secure a supply of monkeypox vaccines.

(Single Plenary, 5 August 2022)